AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. has announced the completion of a USD 37 million Series A financing round.

This round was led by existing investor, InnoPinnacle Fund, with participation from new investors including Yuanbio Venture Capital, Qiming Venture Partners, Hankang Capital, and Genesis Capital.

The proceeds from the financing will further support the clinical development of AHB-137, AusperBio's lead product candidate. Additionally, the funds will advance its proprietary Med-Oligo technology platform and its product pipelines.

Dr. Guofeng Cheng, co-founder and CEO of AusperBio, commented, "We are immensely grateful for the continued support from our existing investors and are very pleased to welcome new investors to the company. This financing round represents a significant milestone that recognizes our scientific and clinical achievements to date. The shared commitment from our investors to developing new therapeutics for CHB patients is truly inspiring. With this funding, together with the recent Breakthrough Therapy Designation (BTD) from China's CDE, we are well-positioned to rapidly advance the clinical development of AHB-137 and move closer to providing a vital new treatment option for patients with CHB."

AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on curing chronic hepatitis B infection.

The company has developed a proprietary Med-Oligo ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design.

Combining with efficient targeted delivery conjugation technologies, the modular Med-Oligo Platform empowers ASO therapeutics to treat a broad range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.